Using Lessons From Toxic Shock Syndrome to Enhance Breast Cancer Immunotherapy

A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer

AI Ali, M Wang, B Von Scheidt, PM Dominguez, AJ Harrison, DGM Tantalo, J Kang, AJ Oliver, JD Chan, X Du, Y Bai, B Lee, RW Johnstone, PK Darcy, MH Kershaw, CY Slaney

2021-11-15

Purpose: In this article, we describe a combination chimeric antigen receptor (CAR) T-cell therapy that eradicated the majority of..

Cross-talk between tumors at anatomically distinct sites

AJ Oliver, PK Darcy, JA Trapani, MH Kershaw, CY Slaney

2021-01-01

Cancer tissue is not homogenous, and individual metastases at different anatomical locations can differ from the primary tumor and..

Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells

JD Chan, B von Scheidt, B Zeng, AJ Oliver, AS Davey, AI Ali, R Thomas, JA Trapani, PK Darcy, MH Kershaw, R Dolcetti, CY Slaney

2020-01-01

Objectives: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is a form of cancer immunotherapy that has achie..

Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

AJ Oliver, SP Keam, B von Scheidt, DJ Zanker, AJ Harrison, DGM Tantalo, PK Darcy, MH Kershaw, CY Slaney

2020-01-01

The presence of a tumor can alter host immunity systematically. The immune-tumor interaction in one site may impact the local immu..

Enterotoxins can support CAR T cells against solid tumors

B Von Scheidt, M Wang, AJ Oliver, JD Chan, MK Jana, AI Ali, F Clow, JD Fraser, KM Quinn, PK Darcy, MH Kershaw, CY Slaney

2019-12-10

Responses of solid tumors to chimeric antigen receptor (CAR) T cell therapy are often minimal. This is potentially due to a lack o..

Genetic redirection of T cells for the treatment of pancreatic cancer

AI Ali, AJ Oliver, T Samiei, JD Chan, MH Kershaw, CY Slaney

2019-01-01

Conventional treatments for pancreatic cancer are largely ineffective, and the prognosis for the vast majority of patients is poor..

Tissue-specific tumor microenvironments influence responses to immunotherapies

AJ Oliver, AS Davey, SP Keam, S Mardiana, JD Chan, B von Scheidt, PA Beavis, IG House, JRM Van Audernaerde, PK Darcy, MH Kershaw, CY Slaney

2019-01-01

Objectives: Investigation of variable response rates to cancer immunotherapies has exposed the immunosuppressive tumor microenviro..

CARs versus biTEs: A comparison between T cell–redirection strategies for cancer treatment

CY Slaney, P Wang, PK Darcy, MH Kershaw

2018-08-01

The redirection of T cells against tumors holds much promise for the treatment of cancer. Two main approaches for T-cell redirecti..